NO-independent regulatory site on soluble guanylate cyclase

@article{Stasch2001NOindependentRS,
  title={NO-independent regulatory site on soluble guanylate cyclase},
  author={J. -P. Stasch and Eva-Maria Becker and Cristina Alonso-Alija and Heiner Apeler and Klaus Dembowsky and Achim Feurer and Rupert Gerzer and Torsten Minuth and Elisabeth Perzborn and Ulrich Pleiss and Henning Schröder and Werner Dr Schroeder and Elke Stahl and Wolfram Steinke and Alexander T. Straub and Matthias Schramm},
  journal={Nature},
  year={2001},
  volume={410},
  pages={212-215}
}
Nitric oxide (NO) is a widespread, potent, biological mediator that has many physiological and pathophysiological roles. Research in the field of NO appears to have followed a straightforward path, and the findings have been progressive: NO and cyclic GMP are involved in vasodilatation; glycerol trinitrate relaxes vascular smooth muscles by bioconversion to NO; mammalian cells synthesize NO; and last, NO mediates vasodilatation by stimulating the soluble guanylate cyclase (sGC), a heterodimeric… 
Structure and regulation of soluble guanylate cyclase.
TLDR
This review summarizes the current understanding of sGC structure and regulation as well as recent developments in NO signaling to aid therapeutic intervention in diseases involving the NO/cGMP-signaling pathway.
Guanylate Cyclase and Cyclic GMP
The NO/cGMP signalling cascade participates in the regulation of physiological parameters such as smooth muscle relaxation, inhibition of platelet aggregation, and neuronal transmission. cGMP is
Soluble guanylate cyclase in NO signaling transduction
Abstract Nitric oxide (NO), a signaling molecule in the cardiovascular system, has been receiving increasing attention since Furchgott, Ignarro, and Murad were awarded the Nobel Prize in Physiology
Soluble Guanylyl Cyclase: Physiological Role as an NO Receptor and the Potential Molecular Target for Therapeutic Application
  • M. Nakane
  • Medicine, Biology
    Clinical chemistry and laboratory medicine
  • 2003
TLDR
The NO/cGMP signal transduction pathway is reviewed and soluble guanylyl cyclase modulators are defined as a novel approach for the treatment of cardiovascular diseases and erectile dysfunction.
NO-independent, haem-dependent soluble guanylate cyclase stimulators.
TLDR
Pharmacological stimulators of sGC may be beneficial in the treatment of a range of diseases, including systemic and pulmonary hypertension, heart failure, atherosclerosis, erectile dysfunction, and renal fibrosis.
Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system.
TLDR
It is concluded that the majority of NO-sensitive GC is not required for cGMP-forming activity but as NO receptor reserve to increase sensitivity toward the labile messenger NO in vivo.
The Mechanism of Allosteric Regulation in Soluble Guanylate Cyclase
Nitric oxide (NO), a reactive diatomic gas and a potent signaling molecule, is required for proper cardiovascular functioning. Soluble guanylate cyclase (sGC), a heterodimeric heme protein, is the
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
TLDR
ODQ is the first inhibitor that acts selectively at the level of a physiological NO "receptor" and, as such, is likely to prove useful for investigating the function of the cGMP pathway in NO signal transduction.
Mechanism of YC-1-induced activation of soluble guanylyl cyclase.
TLDR
Results indicate that YC-1 increases the maximal catalytic rate and sensitizes the enzyme toward its gaseous activators by binding to an allosteric site on sGC molecules, thereby reducing the ligand dissociation rate from the heme group.
Human soluble guanylate cyclase: functional expression and revised isoenzyme family.
TLDR
Having access to the human key enzyme of NO signalling will now permit the study of novel sGC-modulating compounds with therapeutic potential, as both alpha and beta subunits were detected in human tissues, suggesting co-expression also in vivo.
Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery.
TLDR
Results suggest that ODQ inhibits nitrovasodilator-induced and endothelium-dependent relaxation through inhibition of guanylyl cyclase activation, but also point to the presence of a cyclic GMP-independent component of relaxation in bovine pulmonary artery.
Sensitizing soluble guanylyl cyclase to become a highly CO‐sensitive enzyme.
TLDR
The results obtained with YC‐1 reveal that CO is capable of stimulating sGC to a degree similar to NO, and thus provide the molecular basis for CO functioning as a signaling molecule.
The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets.
TLDR
YC-1-like substances are interesting tools for the development of new cardiovascular drugs with vasodilatory and antithrombotic properties and synergize with NO, the physiologic stimulator of sGC.
Effects of the soluble guanylyl cyclase activator, YC‐1, on vascular tone, cyclic GMP levels and phosphodiesterase activity
TLDR
YC‐1 is a highly effective vasodilator compound with a prolonged duration of action, and mechanisms that are unprecedented for any previously known sGC activator.
Generation and characterization of a stable soluble guanylate cyclase-overexpressing CHO cell line.
TLDR
A simple, sensitive, and useful bioassay method is generated to characterize all types of sGC activators on the cellular level without the need of primary cell culture, several transfections, or purifying enzyme from biological materials.
Localization of the heme binding region in soluble guanylate cyclase.
TLDR
The data suggest that the heme in the beta1(1-385) is similar to that in the heterodimeric sGC, and suggests that the N-terminal region of thebeta1 subunit of sGC is itself sufficient for heme binding.
Effect of YC‐1, an NO‐independent, superoxide‐sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators
TLDR
The results indicate that YC‐1 is an NO‐independent, O2−‐sensitive, direct activator of sGC in VSMC and exerts vasorelaxation by increasing intracellular cyclic GMP levels and the synergism revealed in this in vitro study suggests that low doses of YC-1 may be of therapeutic value by permitting the reduction of nitrovasodilator dosage.
...
1
2
3
4
5
...